Examine: Pandemic telehealth use linked to decrease opioid overdose threat

Receiving opioid use disorder-related telehealth care in the course of the COVID-19 pandemic was related to decrease odds of medically handled overdose and higher retention utilizing medicines like methadone and buprenorphine, based on a research revealed in JAMA Psychiatry

The analysis used information from Medicare fee-for-service beneficiaries ages 18 and older who had acquired a analysis for opioid use dysfunction based mostly on ICD-10 codes. It was divided into two teams: a prepandemic cohort of 105, 240 beneficiaries and a pandemic cohort of 70, 538. 

Researchers discovered 19.6% of beneficiaries within the pandemic group acquired OUD-related telehealth companies in the course of the research interval, in contrast with solely 0.6% of sufferers within the prepandemic cohort. They had been additionally extra more likely to entry behavioral health-related digital care at 41%, in contrast with 1.9% within the prepandemic group. Moreover, 12.6% of pandemic beneficiaries accessed medicines for OUD, like methadone, buprenorphine and extended-release naltrexone, in contrast with 10.8% of the prepandemic beneficiaries. 

Although the proportion who skilled a medically handled overdose was related in each teams, the research discovered receiving OUD-related telehealth was related to elevated odds of continuous to make use of medicines for OUD and lowered odds of overdose. 

“Use of telehealth in the course of the pandemic was related to improved retention in care and decreased odds of medically handled overdose, offering help for everlasting adoption,” the research’s authors wrote. “Methods to develop provision of MOUD [medications for opioid use disorder], enhance retention in care and tackle co-occurring bodily and behavioral well being situations are urgently wanted within the context of an escalating overdose disaster.”

WHY IT MATTERS

Although telehealth did enhance entry to medicines for OUD, the researchers famous that solely a small portion of sufferers acquired medicines on 80% or extra of eligible days. 

In addition they discovered racial inequities in entry to care. Non-Hispanic African American beneficiaries had decrease odds of receiving OUD or behavioral health-related telehealth companies and decrease odds for remedy retention. The research additionally discovered greater odds of overdose amongst sufferers who had been non-Hispanic African American, American Indian or Alaska Native, and Asian or Pacific Islander.

Nonetheless, researchers mentioned their research demonstrates telehealth might be an essential option to ship care to folks scuffling with opioid use dysfunction. 

“The growth of telehealth companies for folks with substance use issues in the course of the pandemic has helped to handle boundaries to accessing medical take care of habit all through the nation which have lengthy existed,” Dr. Wilson Compton, deputy director of the Nationwide Institute on Drug Abuse and senior creator of the research, mentioned in an announcement. “Telehealth is a worthwhile service and, when coupled with medicines for opioid use dysfunction, may be lifesaving. This research provides to the proof displaying that expanded entry to those companies may have a longer-term optimistic affect if continued.”

THE LARGER TREND

The opioid epidemic continues to be a serious problem for public well being. In line with the CDC, overdose deaths involving opioids elevated from an estimated 70,029 in 2020 to 80,816 in 2021.

Originally of the COVID-19 pandemic, the Drug Enforcement Administration loosened laws to permit suppliers to prescribe managed substances, like medicines for opioid use dysfunction, with out assembly with sufferers in individual in the course of the public well being emergency.

The PHE was prolonged once more earlier this summer time. Well being and Human Companies Secretary Xavier Becerra has promised to present suppliers 60 days’ discover earlier than it expires. 

Generational Change and Crypto Natives

Assume You Have Lengthy COVID? See Your Main Care Doc First